Latest & greatest articles for atrial fibrillation

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on atrial fibrillation or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on atrial fibrillation and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for atrial fibrillation

1. Comparing Major Bleeding Risk in Outpatients With Atrial Fibrillation or Flutter by Oral Anticoagulant Type (from the National Cardiovascular Disease Registry`s Practice Innovation and Clinical Excellence Registry)

Comparing Major Bleeding Risk in Outpatients With Atrial Fibrillation or Flutter by Oral Anticoagulant Type (from the National Cardiovascular Disease Registry`s Practice Innovation and Clinical Excellence Registry) Comparing Major Bleeding Risk in Outpatients With Atrial Fibrillation or Flutter by Oral Anticoagulant Type (From the National Cardiovascular Disease Registry's Practice Innovation and Clinical Excellence Registry) - PubMed This site needs JavaScript to work properly. Please enable (...) when there aren't any new results Optional text in email: Save Cancel Create a file for external citation management software Create file Cancel Actions Cite Share Permalink Copy Page navigation Am J Cardiol Actions . 2020 May 15;125(10):1500-1507. doi: 10.1016/j.amjcard.2020.02.028. Epub 2020 Mar 5. Comparing Major Bleeding Risk in Outpatients With Atrial Fibrillation or Flutter by Oral Anticoagulant Type (From the National Cardiovascular Disease Registry's Practice Innovation and Clinical

2020 EvidenceUpdates

2. Mobile Health Technology to Improve Care for Patients With Atrial Fibrillation

Mobile Health Technology to Improve Care for Patients With Atrial Fibrillation Mobile Health Technology to Improve Care for Patients With Atrial Fibrillation - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. National Institutes of Health National Library of Medicine National Center for Biotechnology Information Show account info (...) : 10.1016/j.jacc.2020.01.052. Mobile Health Technology to Improve Care for Patients With Atrial Fibrillation , , , , , , , , , , , , , , , , , , , , , , Collaborators, Affiliations Expand Collaborators mAF-App II Trial Investigators : , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Affiliations 1 Medical School of Chinese PLA, Department of Cardiology, Chinese PLA General Hospital, Beijing, China. 2 Liverpool

2020 EvidenceUpdates

3. Does mitral annuloplasty fall under the definition of “valvular atrial fibrillation”?

Does mitral annuloplasty fall under the definition of “valvular atrial fibrillation”? Chiefs’ Inquiry Corner – 3/16/20 – Clinical Correlations Search Chiefs’ Inquiry Corner – 3/16/20 March 16, 2020 2 min read Conventionally, anticoagulation with warfarin has been the prefered method of stroke prevention in patients with valvular atrial fibrillation. In January 2019, the AHA/ACC/HRS Guidelines on the Management of Atrial Fibrillation clarified the definition of valvular a fib, restricting

2020 Clinical Correlations

4. Lifestyle and Risk Factor Modification for Reduction of Atrial Fibrillation: A Scientific Statement From the American Heart Association Full Text available with Trip Pro

Lifestyle and Risk Factor Modification for Reduction of Atrial Fibrillation: A Scientific Statement From the American Heart Association Lifestyle and Risk Factor Modification for Reduction of Atrial Fibrillation: A Scientific Statement From the American Heart Association | Circulation Search Search Hello Guest! Login to your account Email Password Keep me logged in Search Search April 2020 March 2020 February 2020 January 2020 This site uses cookies. By continuing to browse this site you (...) are agreeing to our use of cookies. Free Access article Share on Jump to Free Access article Lifestyle and Risk Factor Modification for Reduction of Atrial Fibrillation: A Scientific Statement From the American Heart Association , MD, FAHA, Chair , MD, Co–Vice Chair , MD, MS, FAHA, Co–Vice Chair , MD, MPH, FAHA , MD, MA, FAHA , MD, FAHA , MD , MD, MSc, FAHA , MBBS, PhD, FAHA , MD Mina K. Chung , Lee L. Eckhardt , Lin Y. Chen , Haitham M. Ahmed , Rakesh Gopinathannair , José A. Joglar , Peter A. Noseworthy

2020 American Heart Association

5. Relation of Frailty to Outcomes After Catheter Ablation of Atrial Fibrillation

Relation of Frailty to Outcomes After Catheter Ablation of Atrial Fibrillation Relation of Frailty to Outcomes After Catheter Ablation of Atrial Fibrillation - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Welcome to the new PubMed. For legacy PubMed go to . Clipboard, Search History, and several other advanced features are temporarily unavailable. National Institutes of Health U.S. National Library of Medicine National (...) . 2020 May 1;125(9):1317-1323. doi: 10.1016/j.amjcard.2020.01.049. Epub 2020 Feb 8. Relation of Frailty to Outcomes After Catheter Ablation of Atrial Fibrillation , , , , , , Affiliations Expand Affiliations 1 Richard A. and Susan F. Smith Center for Outcomes Research in Cardiology, Beth Israel Deaconess Medical Center, Boston, Massachusetts; Harvard Medical School, Boston, Massachusetts. 2 Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester

2020 EvidenceUpdates

6. What is the appropriate initial workup for a patient with newly diagnosed atrial fibrillation?

What is the appropriate initial workup for a patient with newly diagnosed atrial fibrillation? Chiefs’ Inquiry Corner – 3/2/20 – Clinical Correlations Search Chiefs’ Inquiry Corner – 3/2/20 March 2, 2020 2 min read Beyond considerations for rate or rhythm control and anticoagulation, it is recommended that all patients newly diagnosed with atrial fibrillation undergo a basic workup to determine any underlying etiologic causes. This includes a thorough history and physical exam. Additionally

2020 Clinical Correlations

7. External Performance of the HAVOC Score for the Prediction of New Incident Atrial Fibrillation (Abstract)

External Performance of the HAVOC Score for the Prediction of New Incident Atrial Fibrillation Background and Purpose- The HAVOC score (hypertension, age, valvular heart disease, peripheral vascular disease, obesity, congestive heart failure, coronary artery disease) was proposed for the prediction of atrial fibrillation (AF) after cryptogenic stroke. It showed good model discrimination (area under the curve, 0.77). Only 2.5% of patients with a low-risk HAVOC score (ie, 0-4) were diagnosed

2020 EvidenceUpdates

8. Oral Anticoagulation for Patients With Atrial Fibrillation on Long-Term Hemodialysis (Abstract)

Oral Anticoagulation for Patients With Atrial Fibrillation on Long-Term Hemodialysis Patients on long-term dialysis are at increased risk of bleeding. Although oral anticoagulants (OACs) are recommended for atrial fibrillation (AF) to reduce the risk of stroke, randomized trials have excluded these populations. As such, the net clinical benefit of OACs among patients on dialysis is unknown.This study aimed to investigate the efficacy and safety of OACs in patients with AF on long-term

2020 EvidenceUpdates

9. Comparison of the Effect of Age (< 75 Versus >/= 75) on the Efficacy and Safety of Dual Therapy (Dabigatran+Clopidogrel or Ticagrelor) Versus Triple Therapy (Warfarin+Aspirin+Clopidogrel or Ticagrelor) in Patients With Atrial Fibrillation After Percutaneo Full Text available with Trip Pro

Comparison of the Effect of Age (< 75 Versus >/= 75) on the Efficacy and Safety of Dual Therapy (Dabigatran+Clopidogrel or Ticagrelor) Versus Triple Therapy (Warfarin+Aspirin+Clopidogrel or Ticagrelor) in Patients With Atrial Fibrillation After Percutaneo Comparison of the Effect of Age ( - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Welcome to the new PubMed. For legacy PubMed go to . Clipboard, Search History (...) in the 2 age groups, which may help dose selection when using dabigatran dual therapy. Copyright © 2019 The Authors. Published by Elsevier Inc. All rights reserved. Similar articles CP Cannon et al. N Engl J Med 377 (16), 1513-1524. 2017. PMID 28844193. - Randomized Controlled Trial Among patients with atrial fibrillation who had undergone PCI, the risk of bleeding was lower among those who received dual therapy with dabigatran and a P2Y 12 … M Maeng et al. JACC Cardiovasc Interv 12 (23), 2346-2355

2020 EvidenceUpdates

10. Multicenter Randomized Controlled Trial of Vitamin K Antagonist Replacement by Rivaroxaban with or without Vitamin K2 in Hemodialysis Patients with Atrial Fibrillation: the Valkyrie Study Full Text available with Trip Pro

Multicenter Randomized Controlled Trial of Vitamin K Antagonist Replacement by Rivaroxaban with or without Vitamin K2 in Hemodialysis Patients with Atrial Fibrillation: the Valkyrie Study Vitamin K antagonists (VKAs), although commonly used to reduce thromboembolic risk in atrial fibrillation, have been incriminated as probable cause of accelerated vascular calcification (VC) in patients on hemodialysis. Functional vitamin K deficiency may further contribute to their susceptibility for VC. We (...) investigated the effect of vitamin K status on VC progression in 132 patients on hemodialysis with atrial fibrillation treated with VKAs or qualifying for anticoagulation.Patients were randomized to VKAs with target INR 2-3, rivaroxaban 10 mg daily, or rivaroxaban 10 mg daily plus vitamin K2 2000 µg thrice weekly during 18 months. Systemic dp-ucMGP levels were quantified to assess vascular vitamin K status. Cardiac and thoracic aorta calcium scores and pulse wave velocity were measured to evaluate VC

2020 EvidenceUpdates

11. [Nurse-led educational intervention in patients with atrial fibrillation discharged from the emergency department reduces complications and shortterm admissions]. (Abstract)

[Nurse-led educational intervention in patients with atrial fibrillation discharged from the emergency department reduces complications and shortterm admissions]. To assess whether a nurse-led patient educational intervention for patients with atrial fibrillation (AF) discharged from the emergency department (ED) can improve the patients' understanding of arrhythmia and its treatment and reduce the number of complications and arrhythmia-related admissions.Prospective study of an intervention

2019 Emergencias : revista de la Sociedad Espanola de Medicina de Emergencias Controlled trial quality: uncertain

12. Antithrombotic Therapy in Patients With Atrial Fibrillation and Acute Coronary Syndrome Treated Medically or With Percutaneous Coronary Intervention or Undergoing Elective Percutaneous Coronary Intervention: Insights From the AUGUSTUS Trial Full Text available with Trip Pro

Antithrombotic Therapy in Patients With Atrial Fibrillation and Acute Coronary Syndrome Treated Medically or With Percutaneous Coronary Intervention or Undergoing Elective Percutaneous Coronary Intervention: Insights From the AUGUSTUS Trial The safety and efficacy of antithrombotic regimens may differ between patients with atrial fibrillation who have acute coronary syndromes (ACS), treated medically or with percutaneous coronary intervention (PCI), and those undergoing elective PCI.Using a 2×2 (...) factorial design, we compared apixaban with vitamin K antagonists and aspirin with placebo in patients with atrial fibrillation who had ACS or were undergoing PCI and were receiving a P2Y12 inhibitor. We explored bleeding, death and hospitalization, as well as death and ischemic events, by antithrombotic strategy in 3 prespecified subgroups: patients with ACS treated medically, patients with ACS treated with PCI, and those undergoing elective PCI.Of 4614 patients enrolled, 1097 (23.9%) had ACS treated

2019 EvidenceUpdates

13. Association of Anticoagulant Therapy With Risk of Fracture Among Patients With Atrial Fibrillation (Abstract)

Association of Anticoagulant Therapy With Risk of Fracture Among Patients With Atrial Fibrillation Warfarin is prescribed to patients with atrial fibrillation (AF) for the prevention of cardioembolic complications. Whether warfarin adversely affects bone health is controversial. The availability of alternate direct oral anticoagulant (DOAC) options now make it possible to evaluate the comparative safety of warfarin in association with fracture risk.To test the hypothesis that, among patients

2019 EvidenceUpdates

14. Evaluation of the C2HEST Risk Score as a Possible Opportunistic Screening Tool for Incident Atrial Fibrillation in a Healthy Population (From a Nationwide Danish Cohort Study) Full Text available with Trip Pro

Evaluation of the C2HEST Risk Score as a Possible Opportunistic Screening Tool for Incident Atrial Fibrillation in a Healthy Population (From a Nationwide Danish Cohort Study) A simple clinical score, C2HEST (C2: CAD/COPD [1 point each]; H: Hypertension; E: Elderly [Age ≥75, doubled]; S: Systolic HF [doubled]; T: Thyroid disease [hyperthyroidism]) has been proposed to predict incident atrial fibrillation (AF), with good discrimination and internal calibration. To define high-risk patients

2019 EvidenceUpdates

15. Cryoballoon or Radiofrequency Ablation for Atrial Fibrillation Assessed by Continuous Monitoring: A Randomized Clinical Trial (Abstract)

Cryoballoon or Radiofrequency Ablation for Atrial Fibrillation Assessed by Continuous Monitoring: A Randomized Clinical Trial Advanced generation ablation technologies have been developed to achieve more effective pulmonary vein isolation (PVI) and minimize arrhythmia recurrence after atrial fibrillation (AF) ablation.We randomly assigned 346 patients with drug-refractory paroxysmal AF to contact force-guided radiofrequency ablation (CF-RF; n=115), 4-minute cryoballoon ablation (Cryo-4; n=115 (...) ), or 2-minute cryoballoon ablation (Cryo-2; n=116). Follow-up was 12 months. The primary outcome was time to first documented recurrence of symptomatic or asymptomatic atrial tachyarrhythmia (AF, atrial flutter, or atrial tachycardia) between days 91 and 365 after ablation or a repeat ablation procedure at any time. Secondary end points included freedom from symptomatic arrhythmia and AF burden. All patients received an implantable loop recorder.One-year freedom from atrial tachyarrhythmia defined

2019 EvidenceUpdates

16. Subclinical and Device-Detected Atrial Fibrillation: Pondering the Knowledge Gap: A Scientific Statement From the American Heart Association Full Text available with Trip Pro

Subclinical and Device-Detected Atrial Fibrillation: Pondering the Knowledge Gap: A Scientific Statement From the American Heart Association Subclinical and Device-Detected Atrial Fibrillation: Pondering the Knowledge Gap: A Scientific Statement From the American Heart Association | Circulation Search Hello Guest! Login to your account Email Password Keep me logged in Search December 2019 November 2019 October 2019 September 2019 August 2019 July 2019 June 2019 May 2019 April 2019 March 2019 (...) February 2019 January 2019 This site uses cookies. By continuing to browse this site you are agreeing to our use of cookies. Free Access article Share on Jump to Free Access article Subclinical and Device-Detected Atrial Fibrillation: Pondering the Knowledge Gap: A Scientific Statement From the American Heart Association , MD, Chair , MD, FAHA, Vice Chair , MD, MS, FAHA , MD, FAHA , MD, MS, FAHA , MD, FAHA , MD , PhD, RN , MD, MBA , PhD, MPH, MS Peter A. Noseworthy , Elizabeth S. Kaufman , Lin Y. Chen

2019 American Heart Association

17. Osteoporotic Fractures in Patients With Atrial Fibrillation Treated With Conventional Versus Direct Anticoagulants (Abstract)

Osteoporotic Fractures in Patients With Atrial Fibrillation Treated With Conventional Versus Direct Anticoagulants Elderly patients in long-term treatment with vitamin K antagonists (VKAs) are at high risk of osteoporotic fractures compared with the background population. It has been speculated that the choice of oral anticoagulant (OAC) may affect the risk of osteoporotic fractures.The risk of osteoporotic fractures was evaluated among patients with atrial fibrillation treated with VKA (...) (HR: 0.84; 95% CI: 0.76 to 0.93).In a nationwide population, the absolute risk of osteoporotic fractures was low among patients with atrial fibrillation on OAC, but DOAC was associated with a significantly lower risk of osteoporotic fractures compared with VKA.Copyright © 2019 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

2019 EvidenceUpdates

18. Nurse-led vs. usual-care for atrial fibrillation Full Text available with Trip Pro

Nurse-led vs. usual-care for atrial fibrillation Nurse-led integrated care is expected to improve outcome of patients with atrial fibrillation compared with usual-care provided by a medical specialist.We randomized 1375 patients with atrial fibrillation (64 ± 10 years, 44% women, 57% had CHA2DS2-VASc ≥ 2) to receive nurse-led care or usual-care. Nurse-led care was provided by specialized nurses using a decision-support tool, in consultation with the cardiologist. The primary endpoint

2019 EvidenceUpdates

19. Maximum-fixed energy shocks for cardioverting atrial fibrillation Full Text available with Trip Pro

Maximum-fixed energy shocks for cardioverting atrial fibrillation Direct-current cardioversion is one of the most commonly performed procedures in cardiology. Low-escalating energy shocks are common practice but the optimal energy selection is unknown. We compared maximum-fixed and low-escalating energy shocks for cardioverting atrial fibrillation.In a single-centre, single-blinded, randomized trial, we allocated elective atrial fibrillation patients to cardioversion using maximum-fixed (360 (...) -360-360 J) or low-escalating (125-150-200 J) biphasic truncated exponential shocks. The primary endpoint was sinus rhythm 1 min after cardioversion. Safety endpoints were any arrhythmia, myocardial injury, skin burns, and patient-reported pain after cardioversion. We randomized 276 patients, and baseline characteristics were well-balanced between groups (mean ± standard deviation age: 68 ± 9 years, male: 72%, atrial fibrillation duration >1 year: 30%). Sinus rhythm 1 min after cardioversion

2019 EvidenceUpdates

20. Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease. (Abstract)

Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease. There are limited data from randomized trials evaluating the use of antithrombotic therapy in patients with atrial fibrillation and stable coronary artery disease.In a multicenter, open-label trial conducted in Japan, we randomly assigned 2236 patients with atrial fibrillation who had undergone percutaneous coronary intervention (PCI) or coronary-artery bypass grafting (CABG) more than 1 year earlier or who had (...) for noninferiority). Rivaroxaban monotherapy was superior to combination therapy for the primary safety end point, with event rates of 1.62% and 2.76% per patient-year, respectively (hazard ratio, 0.59; 95% CI, 0.39 to 0.89; P = 0.01 for superiority).As antithrombotic therapy, rivaroxaban monotherapy was noninferior to combination therapy for efficacy and superior for safety in patients with atrial fibrillation and stable coronary artery disease. (Funded by the Japan Cardiovascular Research Foundation; AFIRE

2019 NEJM Controlled trial quality: predicted high